TLC completes enrollment for Phase 2 TLC590 study before schedule
Date: 2020-02-14   Author: Saipriya Iyer  Category: #news

TLC completes enrollment for Phase 2 TLC590 study before schedule

TLC recently announced that the patient enrollment in TLC590’s Part 2 of Phase II clinical trial has been completed earlier than it was originally scheduled, which is being performed at four sites across the United States.

For the record, TLC590 is essentially a non-opioid, proprietary BioSeizer that has a sustained ropivacaine release formulation aimed at managing post-surgical pain with a single dose for more than three days. This could potentially reduce the need to take opioids after surgery.

The double-blind, placebo-controlled, randomized and comparator study will be assessing TLC590’s analgesic safety and efficacy for the management of postsurgical pain in patients after bunionectomy. The topline data will be reported sometime in the middle of 2020.

Apparently, after bunionectomy, the dose linearity, relative bioavailability and safety of TLC590 in Part 1 out of the two Phase II clinical trial were recognized based on about 50 patients.

While in a safety and efficacy study of Part 2, nearly 150 patients are randomized at 1:1:1 ratio so that they take TLC590 228 mg single infiltrative local dose, a normal saline placebo or bupivacaine 50mg by the end of their bunionectomy surgery.

The patients are closely monitored for a period of 72 hours and are further followed up for 42 days post-surgery. The area under the curve (AUC) has been considered as the key endpoint ranging from 0-72 hours based on pain rating scales in numbers. The secondary endpoints depict a proportion of patients who are opioid-free and pain-free as well as the total consumption of opioid post-surgery at several time periods and the use of opioids the first time after the operation.

TLC President, George Yeh stated that the data from the previous Phase I/II trial after hernia surgeries, as well as if the current Phase II trial turn out to be positive, it will give the company the confidence to proceed into Phase III trials.

 

Source Credit- https://www.streetinsider.com/Corporate+News/TLC+%28TLC%29+Reports+Early+Completion+of+Patient+Enrollment+in+TLC590+Phase+II+Clinical+Trial+following+Bunionectomy/16453079.html



About Author


Saipriya Iyer

Saipriya Iyer

Saipriya Iyer currently works as a content developer for AlgosOnline. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her belt, she has dabbled with website...

Read More

More from Saipriya


Post Recommendents

ACCC plans to further investigate Qantas’s stake in Alliance
Author: Pankaj Singh

The Australian Competition and Consumer Commission has reportedly announced that it would continue the investigation of the case concerning the acquisition of some stake by Qantas Airways in Alliance Airlines.

<...


Elastin Market: Industry Analysis, Trend, Growth, Opportunity, Forecast 2020-2025
Author: Partha Ray

The latest trending report on global Elastin market research offered by Market Study Report LLC is an informative study covering the market with detailed analysis, the report will assist reader with better understanding and decision making.

...


Hydrolyzed Elastin Market by Manufacturers, Regions, Type and Application Forecast to 2025
Author: Partha Ray

Global Hydrolyzed Elastin Market analysis is provided for the major regions of the world, including development trends, competitive landscape analysis, and key regions development status.

Request a sample Report of Hydrolyzed Ela...